يعرض 1 - 10 نتائج من 57 نتيجة بحث عن '"KIR2DL5"', وقت الاستعلام: 1.39s تنقيح النتائج
  1. 1
    دورية أكاديمية
  2. 2
    دورية أكاديمية
  3. 3
  4. 4
  5. 5
  6. 6
    دورية أكاديمية

    المساهمون: De Re, Valli, Caggiari, Laura, De Zorzi, Mariangela, Repetto, Ombretta, Zignego, ANNA LINDA, Izzo, Francesco, Tornesello, Maria Lina, Buonaguro, Franco Maria, Mangia, Alessandra, Sansonno, Domenico Ettore, Racanelli, Vito, De Vita, Salvatore, Pioltelli, Pietro, Vaccher, Emanuela, Beretta, Massimiliano, Mazzaro, Cesare, Libra, Massimo, Gini, Andrea, Zucchetto, Antonella, Cannizzaro, Renato, De Paoli, Paolo

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/25700262; info:eu-repo/semantics/altIdentifier/wos/WOS:000349789800023; volume:10; issue:2 Article Number: e0117420; firstpage:1; lastpage:21; numberofpages:21; journal:PLOS ONE; http://hdl.handle.net/11586/148270Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84923667055; http://www.plosone.org/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0117420&representation=PDFTest

  7. 7

    المساهمون: Service d’Hématologie Clinique et Thérapie Cellulaire, CHU Bordeaux, CHU Bordeaux [Bordeaux], Biothérapies des maladies génétiques et cancers, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Embodiment, social ineQualities, lifecoUrse epidemiology, cancer and chronIc diseases, intervenTions, methodologY (Equipe 5 - EQUITY), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Service d'Hématologie Clinique et Thérapie Cellulaire [CHU Bordeaux], Université de Bordeaux (UB)-CHU Bordeaux [Bordeaux], Dpt hématologie [CHU Bordeaux], Service d’Hématologie, Hôpital Saint Louis, Paris, Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), ImmunoConcEpT, UMR 5164, Bordeaux, Centre National de la Recherche Scientifique (CNRS), Actions for OnCogenesis understanding and Target Identification in ONcology (ACTION), Institut Bergonié [Bordeaux], UNICANCER-UNICANCER-Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Turcq, Beatrice, Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Immunology from Concept and Experiments to Translation (ImmunoConcept), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS)

    المصدر: Cancer Medicine
    Cancer Medicine, Wiley, 2019, 8 (11), pp.4976-4985. ⟨10.1002/cam4.2371⟩
    Cancer Medicine, 2019, 8 (11), pp.4976-4985. ⟨10.1002/cam4.2371⟩
    Cancer Medicine, Vol 8, Iss 11, Pp 4976-4985 (2019)

    مصطلحات موضوعية: 0301 basic medicine, [SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, Male, Cancer Research, [SDV]Life Sciences [q-bio], 0302 clinical medicine, Receptors, KIR, Genotype, Cytotoxic T cell, Medicine, Receptor, Original Research, Innate lymphoid cell, Remission Induction, Myeloid leukemia, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, treatment‐free remission, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 3. Good health, [SDV] Life Sciences [q-bio], Killer Cells, Natural, Receptors, KIR2DL5, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Imatinib Mesylate, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, Tyrosine kinase, medicine.drug, [SDV.IMM] Life Sciences [q-bio]/Immunology, [SDV.CAN]Life Sciences [q-bio]/Cancer, Antineoplastic Agents, lcsh:RC254-282, Immunophenotyping, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, chronic myeloid leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, [SDV.BBM] Life Sciences [q-bio]/Biochemistry, Molecular Biology, Humans, Radiology, Nuclear Medicine and imaging, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, killer immunoglobulin‐like receptors, Protein Kinase Inhibitors, Aged, business.industry, Clinical Cancer Research, Genetic Variation, Imatinib, natural killer, Discontinuation, 030104 developmental biology, imatinib, Haplotypes, Withholding Treatment, Cancer research, business, Biomarkers

    وصف الملف: application/pdf

  8. 8
    دورية أكاديمية
  9. 9
  10. 10